Puma Biotechnology (United States)

HER kinase inhibition in patients with HER2- and HER3-mutant cancers

David M. Hyman, Sarina A. Piha‐Paul, Helen Won et al. · Nature · 2018 · 752 citations · Full text

Tumor Biology, Oncology, Medicine +8

Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in HER2-Positive Metastatic Breast Cancer Previously Treated With ≥ 2 HER2-Directed Regimens: Phase III NALA Trial

Cristina Saura, Mafalda Oliveira, Yin‐Hsun Feng et al. · Journal of Clinical Oncology · 2020 · 588 citations · Full text

Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial

Miguel Martín, Frankie A. Holmes, Bent Ejlertsen et al. · The Lancet Oncology · 2017 · 578 citations

5-Year Analysis, Breast Oncology, Oncology +10

Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

Arlene Chan, Suzette Delaloge, Frankie A. Holmes et al. · The Lancet Oncology · 2016 · 551 citations

Breast Oncology, Health Sciences, Medicine +9

Neratinib Plus Paclitaxel vs Trastuzumab Plus Paclitaxel in Previously Untreated Metastatic ERBB2-Positive Breast Cancer

Ahmad Awada, Rámón Colomer, Kenichi Inoue et al. · JAMA Oncology · 2016 · 310 citations · Full text